Skip to main content
Quantum Genomics logo

Quantum Genomics — Investor Relations & Filings

Ticker · ALQGC ISIN · FR0011648971 LEI · 969500TFCD8K9RPM9K97 PA Manufacturing
Open in API
Filings indexed 341 across all filing types
Latest filing 2014-12-08 Capital/Financing Update
Country FR France
Listing PA ALQGC

About Quantum Genomics

https://quantum-genomics.com/

Quantum Genomics is a biopharmaceutical company focused on developing a new class of medications for cardiovascular diseases with high unmet medical needs, such as difficult-to-treat or resistant hypertension and heart failure. The company's core research is based on a breakthrough therapeutic approach involving the inhibition of Brain Aminopeptidase A (BAPA). Its lead drug candidate, firibastat, is a first-in-class BAPA inhibitor designed to offer a novel treatment mechanism for managing these conditions.

Recent filings

Filing Released Lang Actions
Mise en place d'un financement moyen terme de 3 M EUR
Capital/Financing Update Classification · 99% confidence The document is a press release dated December 8, 2014, announcing that Quantum Genomics has secured a medium-term financing of 3 M€ through a bond issue ('emprunt obligataire'). This action directly relates to the company's fundraising and capital structure activities. Based on the definitions, this aligns perfectly with the 'Capital/Financing Update' category. Filing Type Code: CAP (Capital/Financing Update).
2014-12-08 French
Quantum Genomics receives a 3 M EUR financing
Capital/Financing Update Classification · 99% confidence The document is a short announcement dated December 8, 2014, titled "Quantum Genomics receives a 3 M€ financing". The core content describes the company receiving medium-term financing through a bond issue. This activity directly relates to fundraising and capital structure changes. Based on the definitions, this aligns perfectly with the 'Capital/Financing Update' category (Code: CAP). The document is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it specifically details a financing event.
2014-12-08 English
Quantum Genomics announces the appointment of Dr Olivier Madonna as Chief Medical Officer
Board/Management Information Classification · 99% confidence The document is an announcement dated November 27th, 2014, titled 'Quantum Genomics announces the appointment of Dr Olivier Madonna as Chief Medical Officer'. It details the hiring and background of a new senior executive (CMO). This directly corresponds to the definition of Board/Management Information, which covers announcements of changes in senior management.
2014-11-27 English
Quantum Genomics annonce la nomination du Dr. Olivier Madonna au poste de Directeur Médical
Board/Management Information Classification · 99% confidence The document is an announcement dated November 27, 2014, titled 'Quantum Genomics annonce la nomination du Dr. Olivier Madonna au poste de Directeur Médical' (Quantum Genomics announces the appointment of Dr. Olivier Madonna as Chief Medical Officer). The content details the appointment of a new senior executive (Dr. Madonna) and includes quotes from the CEO regarding this addition to the management team. This directly corresponds to the definition of Board/Management Information.
2014-11-27 French
Quantum Genomics obtient toutes les autorisations nécessaires pour démarrer son étude clinique de phase II dans l'hypertension artérielle
Regulatory Filings Classification · 95% confidence The document is a press release dated November 17, 2014, announcing that Quantum Genomics has obtained the necessary authorizations (from ANSM and CPP) to start a Phase IIa clinical study for its drug candidate QGC001 for treating arterial hypertension. This type of announcement, detailing clinical trial progress, regulatory milestones, and scientific background, is characteristic of an update intended for investors and the public regarding ongoing development activities. It is not a full Annual Report (10-K), an Earnings Release (ER), or a formal Audit Report (AR). Since it details a significant development milestone (starting a new clinical phase) and provides context on the drug and the disease, it fits best under the general category of corporate or investor-related news that isn't strictly a financial report or a management change. Given the options, this is a specific corporate update. It is not a formal regulatory filing like a 10-K or a simple dividend announcement. It is most closely aligned with an Investor Presentation (IP) in terms of content depth about the product, but it is structured as a press release announcing a development milestone. In the context of the provided definitions, this is a significant corporate announcement that doesn't fit the highly specific financial report codes. It is a general corporate update. Since it is a press release announcing a major operational/development milestone, and not a formal financial report, 'Regulatory Filings' (RNS) serves as the best general category for significant, non-standardized corporate news, although 'IP' might be considered if it were a slide deck. Given the format is a press release announcing a clinical trial start, RNS is the most appropriate fallback for significant operational news not covered elsewhere.
2014-11-17 French
Quantum Genomics receives all regulatory approvals to start its Phase II clinical trial in hypertension
Regulatory Filings Classification · 88% confidence The document is a press release dated November 17, 2014, announcing that Quantum Genomics has received regulatory approvals (ANSM and CPP) to commence a Phase IIa clinical trial for its drug candidate QGC001 for hypertension treatment. This announcement details scientific progress, clinical trial plans, and background information on the disease. It is not a formal regulatory filing like a 10-K, an earnings release (ER), or a transcript (CT). It is a specific update regarding clinical development and regulatory milestones, which fits best under the general category of Investor Relations or a specific regulatory/legal update. Since it is an announcement about a clinical trial milestone and regulatory clearance, and not a formal financial report, it does not fit perfectly into the financial categories. However, given the options, it is a specific corporate announcement that is not covered by DIRS, DIV, MANG, or CAP. It is most closely related to general corporate news or regulatory updates. Since it is a specific announcement about a drug development milestone, and not a general regulatory filing fallback (RNS), the closest fit among the provided options that covers specific corporate developments outside of core financials or governance is often grouped with general corporate news. Given the options, and noting it is a specific corporate update about a drug trial, it is not a standard financial filing. It is a specific corporate announcement. If we must choose from the list, and it is not a financial report, management discussion, or governance document, it falls into the category of general corporate news. Since there is no 'Clinical Trial Update' category, and it is not a financial report, the most appropriate fallback for a specific, non-financial corporate announcement that isn't explicitly covered is RNS (Regulatory Filings - general fallback). However, if we interpret 'LTR' (Legal Proceedings Report) broadly to include regulatory interactions concerning drug approval, it might fit, but LTR usually implies litigation. Given the context of a biopharma company announcing trial commencement based on regulatory approval, this is a significant corporate event announcement. Since it is a specific announcement of a corporate milestone, and not a report itself, it is not an ER or IR. It is a specific announcement. I will classify this as RNS as the best general regulatory/corporate announcement fallback, as it doesn't fit the specific financial or governance codes.
2014-11-17 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.